Primary Care
RSV
More in RSV
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
Nov 11, 2024
"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
Nov 11, 2024
Another vaccine option, updated ACIP recommendations, and data on a new monoclonal antibody
Nov 08, 2024
Decision was based on need for RSV protection in younger people with chronic conditions
Oct 23, 2024
Initial trials were not powered to assess efficacy against RSV-associated hospitalization
Sep 04, 2024
Arexvy now approved for people 50 years and older at increased risk of serious outcomes
Jun 10, 2024